DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
MITIGLINIDE CALCIUM DIHYDRATE
Search structure
Synonyms:
Glufast
Kad-1229
KAD-1229
Mitiglinide calcium dihydrate
Mitiglinide calcium hydrate
Mitiglinide calcium salt dihydrate
S-21403
Status:
Phase 3
Entry Type:
Unknown
Molecule Category:
UNKNOWN
UNII:
9651C21W3Z
Pharmacology
Action
Mechanism of Action
Reference
BLOCKER
Sulfonylurea receptor 1, Kir6.2 blocker
PubMed
PubMed
KEGG
Indications
Mesh Heading
Maximum Phase
Mesh ID
Reference
Diabetes Mellitus, Type 2
3
D003924
ClinicalTrials
Cross References
Resources
Reference
ChEMBL
CHEMBL4298005
FDA SRS
9651C21W3Z
CONTENTS
Structure
Indications
Cross References
×
Active Pharmaceutical Ingredients (APIs)
Scaffolds
Exact
Similarity
SubStructure
Threshold (%) >=
70